HealthDay: Immunotherapy drug did not increase adverse surgery events
A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery.
HealthDay featured the research, recently published in JAMA Otolaryngology - Head & Neck Surgery, that evaluated outcomes during and after surgery when patients with head and neck cancer were given the immunotherapy drug pembrolizumab prior to surgery.
"What we found was that patients who received preoperative treatment with immunotherapy did not have an increase in morbidities around the time of surgery,” said Alice Tang, MD, first author on the study, assistant professor of clinical otolaryngology in UC’s College of Medicine, a UC Health physician and a University of Cincinnati Cancer Center member.
Featured photo at top of Alice Tang, MD, center, with patient. Photo provided by UC Health.
Related Stories
‘Designer drug’ shows early neuroprotective signal in acute ischemic stroke
October 28, 2025
Medscape highlighted new trial results led by the University of Cincinnati's Eva Mistry that found an experimental drug shows promise in protecting injured brain cells for patients with acute ischemic stroke.
UC Board votes to fund design for YMCA renovation
October 28, 2025
At its October 28, 2025 meeting, the University of Cincinnati Board of Trustees approved $5 million in funding to complete all design and pre-construction services required to renovate the interior of a former YMCA building located at 270 Calhoun Street.
Is menstrual fluid ‘the most overlooked opportunity’ in women’s health?
October 27, 2025
The Guardian recently reported that period blood has long been thought of as ‘stinky and useless’, but startups are exploring using the fluid to test for a wide range of health conditions — including endometriosis.